Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Relapsed Myasthenia Gravis after Nivolumab Treatment
Ayumi MitsuneSatoru YanagisawaTatsuro FukuharaEisaku MiyauchiMami MoritaManabu OnoYutaka TojoMasakazu Ichinose
Author information
JOURNAL OPEN ACCESS

2018 Volume 57 Issue 13 Pages 1893-1897

Details
Abstract

Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.

Content from these authors
© 2018 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top